Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. Issue 8 (27th July 2006)

• Record Type: Journal Article
• Authors: Zhu, C-Q; Shih, W; Ling, C-H; Tsao, M-S
• Is Part Of: Journal of clinical pathology. Volume 59:Issue 8(2006)
• Page Start: 790
• Page End: 800
• Publication Date: 2006-07-27
• Subjects: ADC, adenocarcinoma -- CCN, cyclin -- CDK, cyclin-dependent kinase -- ECM, extracellular matrix -- EGFR, epidermal growth factor receptor -- FHIT, fragile histidine triad -- HER, human epidermal growth factor receptor -- HGF, hepatocyte growth factor -- hTERT, human telomerase reverse transcriptase -- IHC, immunohistochemistry -- MMP, matrix metalloproteinase -- mRNA, messenger RNA -- NSCLC, non-small cell lung carcinoma -- PCNA, proliferating cell nuclear antigen -- SQCC, squamous cell carcinoma -- TGF-β, transforming growth factor β -- TIMP, tissue inhibitors of metalloproteinase -- VEGF, vascular endothelial growth factor; Pathology -- Periodicals; Pathology, Molecular -- Periodicals; 616.0705
• DOI: 10.1136/jcp.2005.031351
• Languages: English
• ISSNs: 0021-9746

Abstract

Abstract : Characteristics of the tumour that affect and predict the survival outcome of patients with cancer are prognostic markers for cancer. In non-small cell lung carcinoma (NSCLC), stage is the main determinant of prognosis and the basis for deciding options for treatment. Patients with early-stage tumour are treated by complete surgical resection, which is curative in 40–70% of patients. That there are other factors important in determining the biology of these tumours, especially genes that have a role in metastasis, is indicated. Such factors could potentially be used to further classify patients into groups according to substages that may be treated differently. During the past decade, a large number of proteins that are putatively important in carcinogenesis and cancer biology have been studied for their prognostic value in NSCLC, but none of them have been proved to be sufficiently useful in clinical diagnosis. Several markers (epidermal growth factor receptor, human epidermal growth factor receptor 2, Ki-67, p53 and Bcl-2) have been studied exhaustively. Ki-67, p53 and Bcl-2 are suggested to be important but weak prognostic markers, by meta-analyses of the results. Cyclin E, vascular endothelial growth factor A, p16 INK4A, p27 kip1 and β-catenin are promising candidates, but require further study in large randomised clinical trial samples by using standardised assays and scoring systems. Some issues and inconsistencies in the reported studies to date are highlighted and discussed. A guideline for a multi-phase approach for conducting future studies on prognostic immunohistochemistry markers is proposed here.